The SOLID-TIMI 52 randomized clinical trial evaluated darapladib, a selective lipoprotein-associated phospholipase A2 inhibitor, in patients after ACS and found it did not reduce the risk of coronary events.
The SOLID-TIMI 52 randomized clinical trial evaluated darapladib, a selective lipoprotein-associated phospholipase A2 inhibitor, in patients after ACS and found it did not reduce the risk of coronary events.